Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association
As early and effective antiretroviral therapy has become more widespread, HIV has
transitioned from a progressive, fatal disease to a chronic, manageable disease marked by …
transitioned from a progressive, fatal disease to a chronic, manageable disease marked by …
Aging with HIV in the ART era
E Kaplan-Lewis, JA Aberg, M Lee - Seminars in diagnostic pathology, 2017 - Elsevier
In the current era of therapy for human immunodeficiency virus (HIV), life expectancy for
persons living with HIV (PLWH) approaches that of the general population. This newly …
persons living with HIV (PLWH) approaches that of the general population. This newly …
[HTML][HTML] National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2
TA Jacobson, KC Maki, CE Orringer, PH Jones… - Journal of clinical …, 2015 - Elsevier
Abstract An Expert Panel convened by the National Lipid Association previously developed
a consensus set of recommendations for the patient-centered management of dyslipidemia …
a consensus set of recommendations for the patient-centered management of dyslipidemia …
HIV and global cardiovascular health
Abstract Purpose of Review Because of effective combination antiretroviral therapy, people
living with HIV (PLWH) are living longer but developing chronic age-related conditions …
living with HIV (PLWH) are living longer but developing chronic age-related conditions …
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised …
JA Aberg, CA Sponseller, DJ Ward… - The lancet HIV, 2017 - thelancet.com
Background People living with HIV-1 infection are at greater risk for cardiovascular disease
than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in …
than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in …
Comorbidities of HIV infection: Role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality
D Sviridov, N Mukhamedova, AA Makarov, A Adzhubei… - Aids, 2020 - journals.lww.com
Combination antiretroviral therapy has dramatically changed the outcome of HIV infection,
turning it from a death sentence to a manageable chronic disease. However, comorbidities …
turning it from a death sentence to a manageable chronic disease. However, comorbidities …
[HTML][HTML] Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Introduction As a result of improved safe and effective therapeutic options for human
immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading …
immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading …
Recommendations for managing drug–drug interactions with statins and HIV medications
BS Wiggins, DG Lamprecht, RL Page… - American Journal of …, 2017 - Springer
The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency
virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a …
virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a …
Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study
Q Zhang, Z Chen, Y Wang, Y Peng, S Tan, Y Li… - Frontiers in …, 2024 - frontiersin.org
Background The newly approved third-generation oral anti-HIV-1 drug, ainuovirine (ANV),
was used in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in our …
was used in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in our …
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV
MS Durstenfeld, PY Hsue - Current Opinion in HIV and AIDS, 2021 - journals.lww.com
Our understanding of mechanisms of elevated ASCVD risk in HIV continues to evolve, and
the optimal treatment for CVD in HIV aside from targeting traditional risk factors remains …
the optimal treatment for CVD in HIV aside from targeting traditional risk factors remains …